Reuters logo
BRIEF-Alnylam Pharmaceuticals expects to end 2017 with over $1 bln in cash, cash equivalents, fixed income marketable securities
2017年6月6日 / 下午1点41分 / 5 个月前

BRIEF-Alnylam Pharmaceuticals expects to end 2017 with over $1 bln in cash, cash equivalents, fixed income marketable securities

June 6 (Reuters) - Alnylam Pharmaceuticals Inc

* Company updated its cash guidance for year ending december 31, 2017 - sec filing

* Alnylam Pharmaceuticals-now expects to end 2017 with over $1.0 billion in cash, cash equivalents, fixed income marketable securities, restricted investments Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below